Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
Angela Moran(University of Oxford), Lauri Lehtimäki(Tampere University Hospital), Catherine Borg(University of Oxford), Sanjay Ramakrishnan(The University of Western Australia), Simon Couillard(Université de Sherbrooke), Ian Pavord(University of Oxford), Clare Connolly(University of Oxford), Christine Mwasuku(National Institute for Health and Care Research), Timothy Hinks(University of Oxford)
Cited by 76
Related Papers
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
|The Lancet Respiratory Medicine|2015|584
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
|The Lancet|2021|310
Eosinophilic and Noneosinophilic Asthma
|CHEST Journal|2021|262
Severe eosinophilic asthma: a roadmap to consensus
|European Respiratory Journal|2017|187